Bluejay Diagnostics Inc. is a forward-thinking medical technology company dedicated to transforming patient care through its innovative diagnostic solutions, emphasizing early disease detection. The firm employs a proprietary platform that integrates advanced artificial intelligence with point-of-care testing to enhance diagnostic accuracy and expedite results, empowering healthcare providers with crucial insights in real-time. With a strong commitment to research and development, Bluejay is strategically positioned to address significant healthcare challenges and meet the increasing demand for reliable, innovative diagnostic tools in an evolving medical environment.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 48,910 |
| EBITDA | $-6.85M |
| Operating Margin | 0.00% |
| Return on Equity | -171.60% |
| Return on Assets | -79.60% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $4.04 |
| Price-to-Book | 0.28 |
| Price-to-Sales (TTM) | 54.99 |
| EV/Revenue | 5.67 |
| EV/EBITDA | -0.10 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $1.03M |
| Float | 879,950 |
| % Insiders | 6.07% |
| % Institutions | 10.62% |
$8.5 million upfront with up to approximately $15.1 million of potential additional gross proceeds upon the exercise in full of warrants
ACTON, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (“Bluejay” or the “Company”), a medical diagnostics company focused on rapid, near-patient testing, today announced the successful enrollment of 624 patients in its ongoing SYMON-II Trial, a pivotal clinical study evaluating the Company's Symphony™ platform for interleukin-6 (IL-6) testing in critical care settings to determine patient acuity for sepsis triage and monitoring.
